April 28, 2026, 2:07 PM EDT. Amneal Pharmaceuticals (AMRX) has outperformed its sector with a 62.2% rise over 12 months against a 3.1% gain in its Zacks sub-industry. Despite a slight 0.2% dip year-to-date, the stock remains attractive at a valuation of 1.69 times sales. Amneal's strategic shift toward higher-margin Specialty products and disciplined operations boosted its adjusted gross margin by 50 basis points to 43% in 2025. The company expects steady 2026 revenues between $3.05 billion and $3.15 billion, with improved profitability reflected in adjusted EBITDA guidance of $740 million to $770 million and EPS of 95 cents to $1.05. Cash flow and leverage trends also improved, supporting a balanced financial outlook amid generics pricing pressure.